Vorabodies are single domain antibodies that are specifically engineered to directly access and maintain activity within inflamed tissue. Our platform combines multiple unique attributes to differentiate from all other therapeutics.
Our single domain antibodies are as potent and specific as monoclonal antibodies. We can link several domains together into one molecule to achieve multi-target specificity and unlock greater efficacy.
Their small size facilitates tissue penetration and Sorriso engineering results in high stability among intestinal and inflammatory proteases. Our therapeutics are locally delivered, either oral or inhaled, and remain functional within inflamed tissue.
We have developed a robust and scalable yeast production method yielding an attractive cost of goods. Our therapeutics are highly stable at room temperature and 37oC, eliminating cold chain reliance.